3-17
Full drug name: Zygel (ZYN002) – CBD Transdermal Gel
Phases: Phase 2: ZYN002 – CBD Transdermal Gel; Phase 3: Placebo Transdermal Gel
Results: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome


